Abstract
Extracorporeal carbon dioxide removal (ECCO2R) is an emerging technique designed to reduce carbon dioxide (CO2) levels in venous blood while enabling lung-protective ventilation or alleviating the work of breathing. Unlike high-flow extracorporeal membrane oxygenation (ECMO), ECCO2R operates at lower blood flows (0.4–1.5 L/min), making it less invasive, with smaller cannulas and simpler devices. Despite encouraging results in controlling respiratory acidosis, its broader adoption is hindered by complications, including haemolysis, thrombosis, and bleeding. Technological advances, including enhanced membrane design, gas exchange efficiency, and anticoagulation strategies, are essential to improving safety and efficacy. Innovations such as wearable prototypes that adapt CO2 removal to patient activity and catheter-based systems for lower blood flow are expanding the potential applications of ECCO2R, including as a bridge-to-lung transplantation and in outpatient settings. Promising experimental approaches include respiratory dialysis, carbonic anhydrase-coated membranes, and electrodialysis to maximise CO2 removal. Further research is needed to optimise device performance, develop cost-effective systems, and establish standardised protocols for safe clinical implementation. As the technology matures, integration with artificial intelligence (AI) and machine learning may personalise therapy, improving outcomes. Ongoing clinical trials will be pivotal in addressing these challenges, ultimately enhancing the role of ECCO2R in critical care and its accessibility across healthcare settings.
Key Points
- ECCO₂R as an Alternative to ECMO: Unlike ECMO, which supports both oxygenation and CO₂ removal, ECCO₂R operates at lower blood flows (0.4–1.5 L/min) and is primarily designed to control hypercapnia while enabling lung-protective ventilation strategies.
- Applications in ARDS and COPD: ECCO₂R is most commonly studied in acute respiratory distress syndrome (ARDS) and acute exacerbations of chronic obstructive pulmonary disease (AECOPD), where reducing mechanical ventilation intensity is crucial for minimizing ventilator-induced lung injury.
- Limitations and Safety Concerns: Complications such as hemolysis, thrombosis, and bleeding hinder the broader adoption of ECCO₂R. Higher-flow devices (>500 mL/min) provide better CO₂ clearance but may increase shear stress and coagulation risks.
- Technological Advances in ECCO₂R Devices: New membrane designs, including carbonic anhydrase-coated membranes and electrodialysis, enhance CO₂ removal efficiency while minimizing blood trauma.
- Hemolysis and Thrombosis Risks: Shear stress from extracorporeal circuits contributes to red blood cell destruction and coagulation activation, requiring optimized anticoagulation strategies such as citrate-based anticoagulation over heparin.
- ECCO₂R in Avoiding Intubation: In COPD patients failing non-invasive ventilation, ECCO₂R may help avoid intubation, though data on mortality benefits remain inconclusive.
- ECCO₂R as a Bridge to Lung Transplantation: Patients with end-stage lung disease awaiting transplantation may benefit from ECCO₂R to maintain gas exchange while avoiding the risks of invasive mechanical ventilation.
- AI and Personalized ECCO₂R Therapy: The future of ECCO₂R includes AI-driven algorithms to adjust CO₂ removal in real-time, optimizing patient-specific settings to improve efficacy and safety.
- Integration with Renal Replacement Therapy (RRT): Some ECCO₂R systems are being combined with renal support to provide simultaneous CO₂ clearance and fluid management in critically ill patients.
- Future Research and Clinical Trials: Large-scale randomized trials are needed to establish the clinical efficacy of ECCO₂R, particularly in comparison to standard ventilation strategies and ECMO alternatives.
